These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3225769)

  • 21. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline.
    Emeje M; John-Africa L; Isimi Y; Kunle O; Ofoefule S
    Acta Pharm; 2012 Mar; 62(1):71-82. PubMed ID: 22472450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of ofloxacin sustained release pellets.
    Cui Y; Zhang Y; Tang X
    Int J Pharm; 2008 Aug; 360(1-2):47-52. PubMed ID: 18538518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration.
    Steinijans VW; Sauter R; Böhm A; Staudinger H
    Arzneimittelforschung; 1988 Aug; 38(8A):1241-50. PubMed ID: 3190813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sintering of wax for controlling release from pellets.
    Singh R; Poddar SS; Chivate A
    AAPS PharmSciTech; 2007 Sep; 8(3):E74. PubMed ID: 17915824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the coat quality of sustained release pellets by individual pellet dissolution methodology.
    Xu M; Liew CV; Heng PWS
    Int J Pharm; 2015 Jan; 478(1):318-327. PubMed ID: 25435182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coatings from blends of Eudragit® RL and L55: a novel approach in pH-controlled drug release.
    Wulff R; Leopold CS
    Int J Pharm; 2014 Dec; 476(1-2):78-87. PubMed ID: 25239771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Theophylline-controlled release preparations and fatty food: an in vitro study using the rotating dialysis cell method.
    el-Arini SK; Shiu GK; Skelly JP
    Pharm Res; 1990 Nov; 7(11):1134-40. PubMed ID: 2293211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drug-related problems. II. Bioavailability and tolerance assessment in dogs.
    Timmermans J; Amighi K; Puigdevall J; Baltes E; Moës AJ
    Drug Dev Ind Pharm; 1998 Jun; 24(6):517-25. PubMed ID: 9876617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro and in-vivo characterisation of two sustained release formulations for the antidepressant rolipram.
    Pfeffer M; Sauerbrey N; Windt-Hanke F; Krause W
    Arzneimittelforschung; 1990 Nov; 40(11):1191-4. PubMed ID: 2085329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and in vitro-in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium.
    Fu J; Wang X; Xu L; Meng J; Weng Y; Li G; He H; Tang X
    Int J Pharm; 2011 Mar; 406(1-2):84-90. PubMed ID: 21219996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation in high-shear mixer of sustained-release pellets by melt pelletisation.
    Voinovich D; Moneghini M; Perissutti B; Filipovic-Grcic J; Grabnar I
    Int J Pharm; 2000 Aug; 203(1-2):235-44. PubMed ID: 10967445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of drug release from pellets coated with different shellac types.
    Farag Y; Leopold CS
    Drug Dev Ind Pharm; 2011 Feb; 37(2):193-200. PubMed ID: 21073321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a novel osmotically driven drug delivery system for weakly basic drugs.
    Guthmann C; Lipp R; Wagner T; Kranz H
    Eur J Pharm Biopharm; 2008 Jun; 69(2):667-74. PubMed ID: 18226884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability.
    Xu L; Luo Y; Feng J; Xu M; Tao X; He H; Tang X
    Int J Pharm; 2012 Jan; 422(1-2):9-16. PubMed ID: 22001837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect.
    Miao Y; Chen G; Ren L; Pingkai O
    Drug Deliv; 2016 Sep; 23(7):2163-2172. PubMed ID: 25148542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. pH-Solubility profile of papaverine hydrochloride and its relationship to the dissolution rate of sustained-release pellets.
    Serajuddin AT; Rosoff M
    J Pharm Sci; 1984 Sep; 73(9):1203-8. PubMed ID: 6491936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
    Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
    Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of food on bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms: Part I.
    Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I
    Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):148-52. PubMed ID: 3699941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wax-based sustained release matrix pellets prepared by a novel freeze pelletization technique I. Formulation and process variables affecting pellet characteristics.
    Cheboyina S; Wyandt CM
    Int J Pharm; 2008 Jul; 359(1-2):158-66. PubMed ID: 18499369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissolution of theophylline from film-coated slow release mini-tablets in various dissolution media.
    Fassihi AR; Munday DL
    J Pharm Pharmacol; 1989 Jun; 41(6):369-72. PubMed ID: 2570830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.